The notch receptors: multi-regulators of PAH development

26 August 2021

A PVRI 2021 Digital webinar

Presentations 

  • Role of notch1 in experimental pulmonary hypertension Ralph Schermuly
  • Notch-BMPR interactions in endothelium in PAH Marlene Rabinovitch
  • Notch3 is a driver and biomarker for PAH Patricia Thistlethwaite 
  • Notch3 lineage and pulmonary vasculopathy Maya Kumar 

Speakers & moderators

Ralph Schermuly, Justus Liebig University Giessen, Germany
Marlene Rabinovitch, Stanford University, USA
Patricia Thistlethwaite, University of California San Diego, USA
Maya Kumar, Stanford University, USA
Share:

Other materials on this topic

5 August 2024

Immature reticulocyte fraction: A novel biomarker of hemodynamic severity in pulmonary arterial hypertension

Various erythropoietic abnormalities are highly prevalent among patients with pulmonary arterial hypertension (PAH) and associated with worse disease severity. Given the poorly understood yet important roles of dysregulated erythropoiesis and iron metabolism in PAH, we sought to further characterize the hematologic and iron profiles in PAH and their relationship to PAH severity.

Pulmonary Circulation
25 February 2021

Keynote lecture session 2021

  • Health and wearables: Is this the dawn of a new age for cardiovascular medicine? Martin Cowie
  • Professor Sheila Glennis Haworth Memorial Lecture - Translational Research on PAH, Jason Yuan 
  • Biomarker Analysis of the PULSAR Study: An Ongoing Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of PAH, Marc Humbert
  • Switching from PDE5i to riociguat in patients with PAH: The REPLACE study, Raymond Benza
  • A diagnostic miRNA signature for PAH using a consensus machine learning approach (Rupert Swift Award 2021), Niamh Errington
PVRI Digital Webinar Series